Biotechnology firms are coming around to a harsh reality: The gravy days are over.
These small, innovative drug companies were once an investment darling, able to secure millions of dollars from venture capitalists and even more later through public offerings. But in recent years, venture financing for biotech has been in decline, due to the tough economic environment and poor returns from stock offerings.
{iframe}http://online.wsj.com/article/SB10001424052970203961204577267814201399918.html?mod=WSJ_business_whatsNews{/iframe}